43 related articles for article (PubMed ID: 17727334)
1. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.
Harrop R; Ryan MG; Myers KA; Redchenko I; Kingsman SM; Carroll MW
Cancer Immunol Immunother; 2006 Sep; 55(9):1081-90. PubMed ID: 16311730
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Griffiths R; Steven N; Hawkins RE
Cancer Immunol Immunother; 2008 Jul; 57(7):977-86. PubMed ID: 18060404
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
4. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
Harrop R; Treasure P; de Belin J; Kelleher M; Bolton G; Naylor S; Shingler WH
Cancer Immunol Immunother; 2012 Dec; 61(12):2283-94. PubMed ID: 22692758
[TBL] [Abstract][Full Text] [Related]
5. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
Harrop R; Shingler WH; McDonald M; Treasure P; Amato RJ; Hawkins RE; Kaufman HL; de Belin J; Kelleher M; Goonewardena M; Naylor S
Cancer Immunol Immunother; 2011 Jun; 60(6):829-37. PubMed ID: 21387109
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.
Harrop R; Chu F; Gabrail N; Srinivas S; Blount D; Ferrari A
Cancer Immunol Immunother; 2013 Sep; 62(9):1511-20. PubMed ID: 23877659
[TBL] [Abstract][Full Text] [Related]
7. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).
Elkord E; Dangoor A; Burt DJ; Southgate TD; Daayana S; Harrop R; Drijfhout JW; Sherlock D; Hawkins RE; Stern PL
Cancer Immunol Immunother; 2009 Oct; 58(10):1657-67. PubMed ID: 19221742
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
Michael A; Wilson W; Sunshine S; Annels N; Harrop R; Blount D; Pandha H; Lord R; Ngai Y; Nicum S; Stylianou L; Gwyther S; McNeish IA; Hackshaw A; Ledermann J
Int J Gynecol Cancer; 2024 May; ():. PubMed ID: 38760075
[TBL] [Abstract][Full Text] [Related]
9. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.
Stern PL; Harrop R
Cancer Immunol Immunother; 2017 Apr; 66(4):415-426. PubMed ID: 27757559
[TBL] [Abstract][Full Text] [Related]
10. The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosis.
Bella Á; Melero I; Berraondo P; Aranda F
Oncoimmunology; 2023; 12(1):2285106. PubMed ID: 38126032
[TBL] [Abstract][Full Text] [Related]
11. A novel 5T4-targeting antibody-drug conjugate H6-DM4 exhibits potent therapeutic efficacy in gastrointestinal tumor xenograft models.
Wang R; Lai Q; Tang L; Tao Y; Yao Y; Liu Y; Lu Y; Shen C; Lu R; Fan C; Zhang R; Wang Y; Yu L; Yang T; Wu Y; Peng Y; Wei X; Fu Y; Lai W; Gou L; Yang J
Am J Cancer Res; 2018; 8(4):610-623. PubMed ID: 29736307
[TBL] [Abstract][Full Text] [Related]
12. Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.
Amato RJ; Stepankiw M
Clin Med Insights Oncol; 2012; 6():67-73. PubMed ID: 22253556
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
Biswas S; Eisen T
Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
[TBL] [Abstract][Full Text] [Related]
14. 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2007 Sep; 7(9):1463-9. PubMed ID: 17727334
[TBL] [Abstract][Full Text] [Related]
15. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
Amato RJ; Stepankiw M
Future Oncol; 2012 Mar; 8(3):231-7. PubMed ID: 22409460
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
[TBL] [Abstract][Full Text] [Related]
19. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
Mulryan K; Ryan MG; Myers KA; Shaw D; Wang W; Kingsman SM; Stern PL; Carroll MW
Mol Cancer Ther; 2002 Oct; 1(12):1129-37. PubMed ID: 12481437
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
